Simcere Pharmaceutical misses Q2 estimates, stock dips

Simcere Pharmaceutical (SCR -0.7%) slips after its Q2 earnings miss on both EPS and revenue estimates.

Total revenue slid 3% Y/Y, negatively impacted by the government's pricing policy, government restrictions on the use of antibiotics and market competition.

Gross margin from continuing operations decreased to 83.1%, compared to 84.5% for the same period in 2012.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs